KPV
Also known as: Lys-Pro-Val, α-MSH C-terminal tripeptide
Overview
KPV is a tripeptide (Lys-Pro-Val) representing the C-terminal three amino acids of alpha-melanocyte stimulating hormone (α-MSH). It retains the anti-inflammatory properties of the parent melanocortin peptide without its melanotropic or sexual side effects. Research has demonstrated strong anti-inflammatory activity in intestinal epithelial cells, and oral KPV nanoparticle delivery has shown efficacy in colitis models. It represents a compelling candidate for inflammatory bowel disease and skin inflammation.
Mechanism of Action
KPV acts on melanocortin receptors (MC1R and potentially others) in immune cells and epithelial tissues, inhibiting NF-κB nuclear translocation and downstream pro-inflammatory cytokine production (IL-6, IL-8, TNF-α). It also acts directly on intracellular pathways through receptor-independent mechanisms in epithelial cells. Nanoparticle-formulated oral KPV selectively targets inflamed colonic mucosa due to enhanced mucosal uptake at sites of barrier disruption.
Potential Benefits
- Anti-inflammatory activity in intestinal epithelial cells
- Reduction of pro-inflammatory cytokines (IL-6, IL-8, TNF-α)
- Potential therapeutic candidate for inflammatory bowel disease
- Skin anti-inflammatory effects
- Well-tolerated due to endogenous origin
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 100-500 mcg/day |
| Beginner | 100-200 mcg/day oral or subcutaneous |
| Intermediate | 300-500 mcg/day |
| Advanced | 500-1000 mcg/day for inflammatory bowel conditions |
| Cycle Duration | 4-8 weeks |
| Cycle Off | 4 weeks |
Oral KPV is effective for GI inflammation due to local intestinal action. Subcutaneous dosing for systemic anti-inflammatory effects. Lower doses effective for IBD-like conditions; higher doses for acute inflammation management.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral Moderate
Effective for GI tract inflammation; tripeptide size allows some survival through proteolytic degradation
Subcutaneous Injection High
Systemic anti-inflammatory effects; consistent bioavailability for skin and immune applications
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving KPV:
IBD and Gut Stack
Intestinal inflammation control, mucosal repair, and antimicrobial protection
All three can be orally administered to target the GI tract; complementary anti-inflammatory and healing mechanisms.
Skin Inflammation Stack
Psoriasis, eczema, and inflammatory skin condition management
KPV reduces NF-κB-driven skin inflammation; GHK-Cu promotes tissue repair and anti-inflammatory collagen remodeling.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 5mg, 10mg |
|---|---|
| BAC Water | 1-2ml per 5mg vial |
| Storage | Refrigerate at 2-8°C after reconstitution |
| Shelf Life | 28-30 days refrigerated |
Need exact syringe measurements?
Amino Acid Sequence
Lys-Pro-Val
Side Effects & Safety
- Minimal reported side effects in preclinical models
Synergistic Compounds
The following compounds have been studied alongside KPV for potential complementary or synergistic effects:
Learn More
References & Further Reading
- [object Object]